Full results from Probiodrug’s lead Phase IIa SAPHIR trial are expected to be announced early in 2017, which will be a major milestone for the pure-play Alzheimer’s disease (AD) company. The trial investigates the effects of first-in-class PQ912, a small molecule glutaminyl cyclase (QC) inhibitor, on AD patients. The differentiated approach in the AD field and likely sufficient cash position of €14.2m until the readout should be supportive to the share price. We value Probiod
07 Sep 2016
First-in-class AD asset to deliver Phase IIa data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First-in-class AD asset to deliver Phase IIa data
Vivoryon Therapeutics N.V. (VVY:AMS) | 0 0 0.0%
- Published:
07 Sep 2016 -
Author:
Dr Jonas Peciulis -
Pages:
13
Full results from Probiodrug’s lead Phase IIa SAPHIR trial are expected to be announced early in 2017, which will be a major milestone for the pure-play Alzheimer’s disease (AD) company. The trial investigates the effects of first-in-class PQ912, a small molecule glutaminyl cyclase (QC) inhibitor, on AD patients. The differentiated approach in the AD field and likely sufficient cash position of €14.2m until the readout should be supportive to the share price. We value Probiod